CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Elotuzumab (BMS-901608; HuLuc63)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01441973
NCT01441973Phase 2Completed
CompareCT.gov

A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma

Bristol-Myers Squibb·interventional·Posted Sep 28, 2011·Updated Jan 23, 2018

In Brief

A Phase 2 clinical trial evaluating Elotuzumab (BMS-901608; HuLuc63) for Smoldering Multiple Myeloma. Completed, enrolled 41 participants across 12 sites.

Detailed Summary

The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoldering Multiple Myeloma
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 28, 2011
Enrollment StartDec 28, 2011
Primary CompletionMay 30, 2014
Study CompletionJan 17, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.8 years ago

Interventions

Elotuzumab (BMS-901608; HuLuc63)biological